Adc Therapeutics Ltd Stock News

The heavy selling pressure might have exhausted for ADC Therapeutics SA (ADCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street

ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0

Upgrades For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform

ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 3

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley's 20th Annual

AMC Entertainment Holdings, Inc. (NYSE: AMC) fell 37.1% to $11.34 as the company's APE preferred shares begin trading on the New York Stock Exchange. The preferred shares were issued to all common st

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. Twin Vee Powercats Co. (NASDAQ: VEEE) shares cl

ADCT earnings call for the period ending June 30, 2022.

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 23.96% and 14.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 23.96% and 14.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?